Pfizer Breast Cancer Drug Posts "Disappointing" Results in Clinical Trials
One of Pfizer's (NYSE: PFE) blockbuster drugs has effectively flopped in a late-stage combination therapy trial. The company announced on Friday that the results of a Phase 3 trial for its Ibrance (Palbociclib) breast cancer drug in the treatment of early stage breast cancer were disappointing.
The results of the study indicate that, when used in combination with post-surgery endocrine therapy, it "is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival (iDFS)."
The trial was conducted on male and female patients with HR-positive, HER2-negative early stage breast cancer.
Source Fool.com
